Alumis (ALMS) EBITDA Margin (2025)
Alumis (ALMS) reported EBITDA Margin of 4819.96% for Q4 2025, up 9.91% quarter-over-quarter from 5350.44% in Q3 2025.
Alumis (ALMS) EBITDA Margin (2025) Analysis & Trends
Alumis (ALMS) has 1 years of EBITDA Margin data on file, last reported at 4819.96% in Q4 2025.
- EBITDA Margin for Q4 2025 came in at 4819.96%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 1011.13% (changed N/A YoY), and the FY2025 annual result was 1011.13%, changed N/A from the prior year.
- EBITDA Margin advanced to 4819.96% in Q4 2025 per ALMS's latest filing, from 5350.44% in the prior quarter.
- Over five years, EBITDA Margin peaked at 2226.22% in Q2 2025 and troughed at 5350.44% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Alumis | 1.99 Bn | 1.90 Bn | - | -4,819.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4,819.96% |
| Sep 30, 2025 | -5,350.44% |
| Jun 30, 2025 | 2,226.22% |
| Mar 31, 2025 | -569.39% |